 Allosterix is a drug design company specializing in the design and development of enzyme inhibitors. The Allosterix platform’s core competency lies in locating an allosteric site in any target enzyme, and designing a short peptide molecule to bind to it. The primary advantage of allosteric inhibition is selectivity, which is the main challenge in the enzyme inhibition industry. Allosterix’s business model is founded on their steadfast commitment to the design of de novo compounds and their continued development until they reach in vivo proof of concept.First Target enzyme – TACE (TNF-α Converting Enzyme) TACE is the main cleaving enzyme for the highly potent inflammatory mediator TNF-a. TACE is found to be over-active in various auto immune diseases (RA, IBD, asthma, psoriasis ect.), EGFR cancers and stroke. Due to the over $15 billion/year market potential, most of the big pharmaceutical companies have pursued an anti-TACE drug for more than a decade. Allosterix has designed TACE inhibitors that are highly potent, selective and stable. These inhibitors have demonstrated very promising results in in vivo mice models. Technology Allosterix has developed a novel drug design strategy based on multi-disciplinary knowledge and state-of-the-art tools. Allosterix designs novel enzyme inhibitors that are targeted to a located allosteric site. A potential allosteric site is defined as any site on enzyme's surface other than the active site. Unlike the active site, allosteric sites are unique, thus drug selectivity/specificity is inherent in the design of the inhibitor. Allosterix’s small molecule inhibitors are very short peptides, which are ideal candidates for oral delivery. Short peptides can also be quickly and easily synthesized. Contact Details Exhibition Representatives Biotechnology |
|
Company Profiles >
Allosterix |